Cel Sci Corporation (CVM)

[lightrock]

Your case for the r/s is pretty strong.

If they have to recap for leaps then preferred is a possibility for that "venture within a venture", I still see those preferred as being tied to revenue similar to "dividend" or "plausible venture that will plausibly equate to dividends"

Maybe they roll in the sale of the facility to that... hmn...

Another reason not to preferred is that it is "not plausible" that a drug candidate can do anything within reasonable timeframe "4-5 years".

They are also not standing very high in any performance category...